Research programme: dual antimuscarinic/beta-2 adrenoceptor agonists - Pfizer

Drug Profile

Research programme: dual antimuscarinic/beta-2 adrenoceptor agonists - Pfizer

Alternative Names: PF-3429281

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in United Kingdom (Inhalation)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in United Kingdom (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top